EU nears deal with Valneva for Covid-19 vaccine

Valneva’s vaccine is developed using a technology based on inactivated viruses, as opposed to the mRNA method used by Pfizer-BioNTech and Moderna. – AFP pic, January 12, 2021.

THE European Commission announced today it has concluded exploratory talks with Franco-Austrian biotechnology laboratory Valneva for the possible purchase of up to 60 million doses of its Covid-19 vaccine.

The EU executive has already signed contracts with six other laboratories and is also in discussions with US firm Novavax to secure 200 million doses. 

Effective July 2018, access to full reports will only be available with a subscription. Sign-up now and enjoy one (1) week free access!

Subscribe Now!

Sign up or sign in here to comment.